Results 1 to 10 of about 20,735 (212)

Immunogenicity, Immune Dynamics, and Subsequent Response to the Booster Dose of Heterologous versus Homologous Prime-Boost Regimens with Adenoviral Vector and mRNA SARS-CoV-2 Vaccine among Liver Transplant Recipients: A Prospective Study [PDF]

Vaccines, 2022
Background: Heterologous prime-boost vaccination potentially augments the immune response against SARS-CoV-2 in liver transplant (LT) recipients. We investigated immunogenicity induced by different primary prime-boost vaccination protocols and the ...
Supachaya Sriphoosanaphan, Sirinporn Suksawatamnuay, Nunthiya Srisoonthorn, Nipaporn Siripon, Panarat Thaimai, Prooksa Ananchuensook, Kessarin Thanapirom, Bunthoon Nonthasoot, Pokrath Hansasuta, Piyawat Komolmit   +9 more
doaj   +4 more sources

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2 [PDF]

Frontiers in Immunology, 2022
BackgroundHeterologous vaccinations against SARS-CoV-2 with ChAdOx1 nCoV-19 and a second dose of an mRNA-based vaccine have been shown to be more immunogenic than homologous ChAdOx1 nCoV-19.
Robert Markewitz, David Juhl, Daniela Pauli, Siegfried Görg, Ralf Junker, Jan Rupp, Sarah Engel, Katja Steinhagen, Victor Herbst, Dorinja Zapf, Christina Krüger, Christian Brockmann, Frank Leypoldt, Justina Dargvainiene, Benjamin Schomburg, Shahpour Sharifzadeh, Lukas Salek Nejad, Klaus-Peter Wandinger, Malte Ziemann   +18 more
doaj   +3 more sources

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [PDF]

Lancet, The, 2021
BACKGROUND. A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi   +2 more
exaly   +5 more sources

Human tonsil organoids reveal innate pathways modulating humoral and cellular responses to ChAdOx1. [PDF]

PLoS Pathog
The COVID-19 pandemic response demonstrated the effectiveness of adenovirus vector vaccines in inducing protective cellular and antibody responses.
Pudjohartono MF, Powell K, Barnes E, Klenerman P, Provine NM.   +4 more
europepmc   +6 more sources

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [PDF]

Lancet, The, 2020
BACKGROUND: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike ...
Pedro M Folegatti, Parvinder Aley, Brian J Angus   +2 more
exaly   +5 more sources

Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines [PDF]

npj Vaccines
Vaccination has proven to be a valuable tool to combat SARS-CoV-2. However, reports of rare adverse reactions such as thrombosis/thrombocytopenia syndrome after ChAdOx1 nCoV-19 vaccination have caused scientific, public and media concern.
Joshua Gardner, Simon Timothy Abrams, Cheng-Hock Toh, Alan L. Parker, Charlotte Lovatt, Phillip L. R. Nicolson, Steve P. Watson, Sophie Grice, Luisa Hering, Munir Pirmohamed, Dean J. Naisbitt   +10 more
doaj   +2 more sources

Immunogenicity and Safety of Half and Full Doses of Heterologous and Homologous COVID-19 Vaccine Boosters After Priming with ChAdOx1 in Adult Participants in Indonesia: A Single-Blinded Randomized Controlled Trial [PDF]

Vaccines
Background: Numerous studies have proved the efficacy of vaccination in reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and the coronavirus disease (COVID-19) burden.
Nina Dwi Putri, Aqila Sakina Zhafira, Pratama Wicaksana, Hindra Irawan Satari, Eddy Fadlyana, Vivi Safitri, Nurlailah Nurlailah, Edwinaditya Sekar Putri, Nidya Putri, Devi Surya Iriyani, Yunita Sri Ulina, Frizka Aprilia, Evi Pratama, Indri Nethalia, Rita Yustisiana, Erlin Qur’atul Aini, Rini Fajarani, Adityo Susilo, Mulya Rahma Karyanti, Ari Prayitno, Hadyana Sukandar, Emma Watts, Nadia Mazarakis, Pretty Multihartina, Vivi Setiawaty, Krisna Nur Andriana Pangesti, Agnes Rengga Indrati, Julitasari Sundoro, Dwi Oktavia Handayani, Cissy B. Kartasasmita, Sri Rezeki Hadinegoro, Kim Mulholland   +31 more
doaj   +2 more sources

Transcriptomic and miRNA Signatures of ChAdOx1 nCoV-19 Vaccine Response Using Machine Learning [PDF]

Life
Vaccination with ChAdOx1 nCoV-19 is an important countermeasure to fight the COVID-19 pandemic. This vaccine enhances human immunoprotection against SARS-CoV-2 by inducing an immune response against the SARS-CoV-2 S protein.
Jinting Lin, Qinglan Ma, Lei Chen, Wei Guo, Kaiyan Feng, Tao Huang, Yu-Dong Cai   +6 more
doaj   +2 more sources

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial [PDF]

Lancet, The, 2021
Rajeka Lazarus, Heike Cappel-Porter, Andrew Carson-Stevens   +2 more
exaly   +3 more sources

Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial. [PDF]

Sci Rep
Fractional dosing of vaccines is a viable strategy to extend COVID-19 vaccine supplies in resource-constrained settings. We did a triple-blinded, multi-site, randomized non-inferiority trial in Nigeria (PACTR202206754734018).
Salako A, Musa A, Ige F, Abdullahi A, James A, Ekama S, Odubela O, Idigbe I, Ajibaye O, Altaf M, Adeneye K, Akinsolu FT, Olojo I, Okwuraiwe A, Egharevba H, Ekpenyong M, Elemuwa U, Ezenyi I, Bitrus F, Odubela O, Oba A, Idris G, Yusuf J, Akande I, Nwaiwu S, Omale L, Oyewunmi O, Agbabiaka A, Eyinade O, Ogunwale J, Garba A, Bello Y, Musa B, Ezejiofor O, Ejiro B, Iwalokun B, Rosenzweig L, Adigwe O, Adeyeye C, Shuaib F, Wicek W, Hamada Y, Ezechi O, Gupta R, Salako B.   +44 more
europepmc   +3 more sources